1. Hoyle M, Rogers G, Garside R, Moxham T, Stein K: The clinical- and cost effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. Submission to NICE as part of STA program. 2008
2. Thompson-Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K: Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment. 2010, 14:
3. NICE: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line). 2010, [
http://guidance.nice.org.uk/TA/Wave17/8
]
4. Briggs A, Sculpher M, Claxton K: Decision modelling for health economic evaluation. 2006, Oxford, UK.: Oxford University Press
5. Collett D: Modelling Survival Data in Medical Research. 2003, Boca Raton: Chapman & Hall/CRC, 2